Dr Khaw enjoys managing all aspects of endocrinology including: Type 1 and 2 Diabetes (including insulin pumps); thyroid diseases; endocrine disorders during pregnancy; PCOS; osteoporosis and bone health; pituitary and adrenal diseases; neuroendocrine tumours and cancer genetic syndromes related to endocrinology.
Dr Khaw Chong Hui graduated from the University of Dublin in 2000 and obtained his postgraduate MRCP (Ireland) in 2003. He subsequently went on to complete his Fellowship in Endocrinology in Malaysia and Australia under the Ministry of Health.
After serving as a Clinical Specialist in Internal Medicine at the Seberang Jaya Hospital, Dr Khaw pursued further training in the field of Endocrinology at Penang Hospital, St Vincent’s Hospital in Sydney, Putrajaya Hospital and the National University of Malaysia Medical Centre (UKM).
Dr Khaw is competent in the management of the full spectrum of diabetes and endocrine conditions. These include diabetes treatment and counselling, obesity treatment, thyroid disorders like hypothyroidism and hyperthyroidism, management of osteoporosis and maintaining bone health, and treatment of pituitary disorders, that require hormonal replacement, e.g. testosterone replacement.
Dr Khaw is fluent in Mandarin, Malay, English and Hokkien. He enjoys listening to classical music and playing the piano in his free time.
Article on “Hemiballismus”. Published in the Irish Medical Journal April 2002 Volume 95 No 4:Pages 123-4. Other authors:Geoghegan, M.F., McCormick, P.A.
Research Publication on “Anti-Saccharomyces Cerevislae Mannan Antibodies Combined with Antineutrophil Cytoplasmic Autoantibodies in Irish Patients with Inflammatory Bowel Disease”. Published in the National Institute of Health Sciences June 2002, Volume 1 Issue 3, Page 9. Other authors: Geogehegan, M., Mc Donnell, C., Beggan, E., Sundram, F., Burke, G.J.
Oral Presentation at the 20th Spring Congress of Korean Diabetic Association on “Prevalence of Glucose Intolerance and Metabolic Syndrome Features in Prior Gestational Diabetes Mellitus (GDM) Women in Penang Hospital”. Authors: Shanty a/p Velaiutham, Chong Hui Khaw, Shueh Lin Lim, Malik Mumtaz, Nor Azizah Aziz, Mohamed Ali Abdul Khader, Amir S Khir.
Poster Presentation at the 89th Endo Society Meeting, Toronto on “Impact Of Dietary Iodine Restriction Pre-radioactive Iodine (I131) Treatment on Urinary Iodide and Response of Radioactive Iodine Treatment at Penang Hospital”. Authors: Shueh Lin Lim, Chee Kin Yoon, Malik Mumtaz, Chong Hui Khaw, Nor Azizah Aziz, Shanty a/p Velaiutham, Wan Nazaimoon, Amir S Khir.
Poster Presentation at the ASEAN Federation of Endocrine Societies (AFES) 2007 on “Cutaneous and Cerebral Manifestation of Juvenile Xanthogranuloma with Hypopituitarism”
“Radioiodine therapy for treatment of thyrotoxicosis.”Authors: Malik Mumtaz, Lim Shueh Lin, Khaw CH, A S M Khir. Published: Malaysian Journal of Medical Sciences, 2009; 16(1): 25 – 33
Poster Presentation at the 92th Endo Society Meeting, San Diego on “Validation of Multi-Frequency Bioelectrical Impedance Analysis (MFBIA) for Measurements of Body Composition: A Study of Growth Hormone and Testosterone Administration in Healthy Adults”. Authors: Chong Hui Khaw, Vita Birzniece, Udo Meinhardt, Ann E Nelson, Ken KY Ho
“Prevalence of glucose intolerance in women with previous gestational diabetes mellitus in Penang Hospital”. Authors: Shanty Vellaiutham, Chong Hui Khaw, Shueh Lin Lim, Malik Mumtaz, Nor Azizah Aziz, Jamilah Baharom, A S M Khir. Published: Journal of the ASEAN Federation of Endocrine Societies 2009; 24 (1) Suppl: 14
“The biochemical parameters related to glucose intolerance in women with previous gestational diabetes mellitus in Penang Hospital”. Authors: Shanty Vellaiutham, Chong Hui Khaw, Shueh Lin Lim, Malik Mumtaz, Nor Azizah Aziz, Jamilah Baharom, Mohamad Ali Kader, Wan Nazaimoon WM, A S M Khir. Published: Journal of the ASEAN Federation of Endocrine Societies 2009; 24 (1) Suppl: 17
Contributed to the “Report of the Acute Coronary Syndrome (ACS) Registry 2006”
Specialist Advisor for Clinical Trial: “A Community based multiple risk factors intervention strategy to prevent Cardiovascular and Chronic Kidney diseases (CORFIS)”
Sub-investigator for Clinical Trial: “Randomized, multinational, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20 mg OD for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors”
Sub-investigator for Clinical Trial: “A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI1356 (5mg administered orally once daily) over 24 weeks in drug naive or previously treated (6 weeks washout) type 2 diabetic patients with insufficient glycaemic control”
Sub-investigator for Clinical Trial: “A Phase IIb/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Range Finding Clinical Trial of MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycaemic Control on Insulin”
Sub-investigator for Clinical Trial: “A 78 week open label extension to trials assessing the safety and efficacy of BI 1356 (5 mg) as monotherapy or in combination with other antidiabetic medications in type 2 diabetic patients”
Sub-investigator for Clinical Trial: “Measuring Body Composition in Patients with Pituitary Disorders using Multi-frequency Bioelectrical Impedance Analysis comparing Dual-energy X-ray Absorptiometry and Bromide dilution”
Chief-investigator for Clinical Trial: “An open-labelled, prospective, randomized, cross-over trial to assess the Impact of Lower Dose vs Conventional Dose Glucocorticoid Replacement on Bone Turnover, Glucose and Cortisol Metabolism and Quality of Life”
Sub-investigator for Clinical Research: “Retrospective chart review of diabetes pregnancy in a Malaysian hospital: the relationship between time of onset of glucose intolerance and occurrence of maternal and fetal complications”
Sub-investigator for Clinical Trial: “A 26-week, randomised, open-labelled, two-arm, parallel-group, treat-to-target trial comparing efficacy and safety of soluble insulin analogue combination (SIAC) twice daily (BID) with biphasic insulin aspart (BIAsp) 30 BID, with or without metformin, with or without DPP-4 inhibitor, with or without pioglitazone in subjects with type 2 diabetes in inadequate glycaemic control on once or twice daily premixed or self-mixed insulin regimen with or without OADs; Trial phase 3a”
Sub-investigator for Clinical Trial: “Randomized double blind, placebo-controlled clinical trial to assess the effects of taspoglutide (RO5073031) on cardiovascular outcomes in subjects with inadequately controlled type 2 diabetes and established cardiovascular disease”
Sub-investigator for Clinical Trial: “A randomised, double-blind, placebo-controlled, 3 parallel group efficacy and safety study of linagliptin 2.5 mg twice daily versus 5 mg once daily over 12 weeks as add-on therapy to a twice daily dosing regimen of metformin in patients with type 2 diabetes mellitus and insufficient glycaemic control”
Sub-investigator for Clinical Trial: “A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled, Study of the Effects of JNJ 28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus”
Sub-investigator for Clinical Trial: “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes and Acute Coronary Syndrome”
Sub-investigator for Clinical Trial: “A multi-center, randomized, open-label, active-controlled study to compare the efficacy, safety and tolerability of taspoglutide (RO5073031) versus insulin glargine in insulin-naive type 2 diabetic patients inadequately controlled with metformin and sulfonylurea combination therapy”
Sub-investigator for Clinical Trial: “Cardiovascular Risk Factors In Women With Previous History of Gestational Diabetes Mellitus in Penang Hospital”
Sub-investigator for Clinical Trial: “A Randomized,Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono-or Dual Combination Oral Antihyperglycemic Therapy”
Sub-investigator for Clinical Trial: “BEGIN™ : ONCE ASIA. A Pan Asian trial comparing efficacy and safety of insulin NN1250 and insulin glargine as add on to OAD(s) in subjects with type 2 diabetes (A 26-week randomised, confirmatory, controlled, open label, multicentre, multinational treat-to-target trial comparing the efficacy and safety of SIBA and insulin glargine, both injected once daily as add on to current OAD treatment in insulin naïve subjects with type 2 diabetes mellitus qualifying for more intensified treatment)”
Sub-investigator for Clinical Trial: “BOOST™ : INTENSIFY ALL. A Pan Asian trial comparing efficacy and safety of NN5401 and biphasic insulin aspart 30 in type 2 diabetes (A 26-week trial, randomised, open-label, two-arm, parallel-group, treat-to-target study comparing efficacy and safety of the soluble insulin analogue combination (SIAC) twice daily with biphasic insulin aspart 30 twice daily, with or without metformin in subjects with type 2 diabetes in inadequate glycaemic control on once or twice daily insulin regimen with or without metformin)”
Sub-investigator for Clinical Trial: “A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 (Canagliflozin) Compared with Sitagliptin and Placebo in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy”
Sub-investigator for Clinical Trial: “A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson’s Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine”
Sub-investigator for Clinical Trial: “The effect of NovoMix® 30, Levemir® or NovoRapid® (alone or in combination) in subjects with type 2 diabetes previously treated with other anti-diabetic medication. A 24-week, international, prospective, multi-centre, open labelled, non-interventional study”
Sub-investigator for Clinical Trial: “The effects of vitamin D supplementation on blood glucose and markers of metabolic syndrome in women with Vitamin D deficiency and previous Gestation Diabetes Mellitus”
Sub-investigator for Poster Presentation at 14th Asia-Oceanic Congress of Endocrinology, KLCC, Poster Title “A Study on Effectiveness of Radioiodine Therapy in Hyperthyroid Patients in Endocrine Clinic, Penang Hospital”
Sub-investigator for Clinical Trial: “Glucose homeostasis, incretin effect and cardiovascular risk burden in youth onset T2DM. A study of the Malaysian population”
Sub-investigator for Clinical Trial : “A Phase III, Multicentre, Double-Blind, Randomized, Placebo- and Metformin-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients with Type 2 Diabletes Mellitus with Inadequate Glycemic Control”
Sub-investigator for Clinical Trial: “A multicenter, international, randomized, parallel group, double-blind, placebo-controlled CArdiovascular Safety & Renal Microvascular outcomE study with LINAgliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk. CARMELINA”
Sub-investigator for Clinical Trial: “A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy”
Second Author for: Eur J Endocrinol. 2015 Jan;172(1):21-8. doi: 10.1530/EJE-14-0660. Epub 2014 Oct 17. A critical evaluation of bioimpedance spectroscopy analysis in estimating body composition during GH treatment: comparison with bromide dilution and dual X-ray absorptiometry.
Principal Investigator: “REAL 1 : Safety and efficacy of once weekly liquid growth hormone (NNC0195-0092) in adults with growth hormone deficiency”
Second Author: “Severe hypertriglyceridemia in a nondiabetic treated with low dose insulin infusion.” CV Tong, S Velaiutham, NA Aziz, SL Lim, CH Khaw. The Medical journal of Malaysia 70 (4), 249
Second Author: “Glycemic control, safety, and adherence when switching from glicla- zide plus metformin to precombined glibenclamide/metformin— branded vs. Generic.“ Phei Ching Lim, Shueh Lin Lim, Chong Hui Khaw, Yen Li Lim, Mohamed Azmi Hassali, Chee Ping Chong. Diabetes 2015 June 64:A656; doi:10.2337/db15-2511-2682
Sub-investigaor: “Glycemic outcome, adherence, adverse drug reaction and cost-effectiveness when changing from gliclazide to gliclazide MR in type 2 diabetes mellitus- A cross- over study of original and generic gliclazide MR”